- Voyageur Pharmaceuticals (TSXV:VM) has finished environmental and geotechnical field work at its Frances Creek project site
- The site assessment included an evaluation of existing baseline conditions within and surrounding the site
- The data, samples, and road assessment gathered during this process will serve as crucial inputs for various planning aspects
- Voyageur Pharmaceuticals Ltd. (VM) opened trading at $0.07 per share
Voyageur Pharmaceuticals (TSXV:VM) has finished environmental and geotechnical field work at its Frances Creek project site.
This was completed in collaboration with Cranbrook B.C.-based Vast Resource Solutions. The detailed site assessment included an evaluation of existing baseline conditions within and surrounding the site. It also involved meticulous collection of soil and rock samples, along with a thorough review of the current and potential site access road.
The data, samples, and road assessment gathered during this process will serve as crucial inputs for various planning aspects, including site soil handling and reclamation, invasive weed management practices, acid rock drainage/metal leaching potential, process area planning, and safe access road options.
Voyageur is a drug manufacturing company focused on the development of barium and iodine active pharmaceutical ingredients and imaging contrast agents for the medical imaging marketplace.
Operating out of Calgary, the company owns a 100 per cent interest in two barium sulphate (barite) projects, including its flagship Frances Creek property, 40 km from Radium Hot Springs, B.C. Voyageur also holds interests in a high-grade iodine, lithium, and bromine brine project situated in Utah. Voyageur recently signed a development and license agreement with Rain Cage Carbon Inc. to develop and manufacture nanocarbon / fullerene-based contrast agents for medical imaging, utilizing EDEN carbon capture technology. Click here to read more.
Voyageur Pharmaceuticals Ltd. (VM) opened trading at $0.07 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
